Revolution Medicines- Warrants (17/12/2026) (RVMDW) has a profit margin of -946.82%, below the Healthcare sector average of 19.13%.
Get informed when a big investor buys or sells
+ FollowAs of Sep 2026
Trailing 12 months ending Sep 2026
Revolution Medicines- Warrants (17/12/2026)'s profit margin stands at -946.82% as of September 2026. That compares with -354.22% in the prior-year period — down 167.3% year over year. That is below the Healthcare sector average of 19.13%. Stockcircle updates this page with the newest filings so you can track how the metric evolves quarter by quarter.
Revolution Medicines- Warrants (17/12/2026) reported -946.82% in profit margin versus -354.22% a year earlier — a 167.3% year-over-year decrease. The historical chart on this page makes it easier to see whether that move is part of a longer pattern.
Revolution Medicines- Warrants (17/12/2026) sits lower the Healthcare benchmark (19.13%) with a profit margin of -946.82%. That is roughly 5049.1% below the sector mean. Peer context matters because what looks expensive or cheap in absolute terms can be normal for the sector.
A profit margin of -946.82% for Revolution Medicines- Warrants (17/12/2026) means each unit of related capital or sales is generating that return rate. Higher is usually better for profitability metrics, but extremely high figures can reflect one-time items or thin equity bases. Review several years of data on this page before extrapolating.
The history chart shows how Revolution Medicines- Warrants (17/12/2026)'s profit margin evolved across reporting periods, while the comparison chart places RVMDW next to similar companies. Use both: a rising metric that still lags peers tells a different story than a rising metric that already leads the group. Growth charts, when available, highlight acceleration or slowdown.